| OSU6162 as add-on in SSRI/SNRI-resistant Depression (NCT05641623) | Göteborg University | 2022-04-21 |
| Synaptic Imaging and Network Activity in Treatment Resistant Depression (NCT05870501) | King's College London | 2021-10-20 |
| Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (NCT04977674) | King's College London | 2021-09-27 |
| Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment (NCT04956016) | Centre Hospitalier Henri Laborit | 2021-08-23 |
| Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation (NCT05390593) | Chang Gung Memorial Hospital | 2021-08-01 |
| Sevoflurane for Treatment-Resistant Depression (NCT05008939) | Shanghai First Maternity and Infant Hospital | 2021-08-01 |
| Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study (NCT04783103) | Universitair Ziekenhuis Brussel | 2021-05-07 |
| IMPase in Treatment-resistant Depression (NCT05117710) | University of Oxford | 2021-04-22 |
| Dopaminergic Dysfunction in Late-Life Depression (NCT04469959) | Vanderbilt University Medical Center | 2021-02-15 |
| Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression (NCT04701866) | Douglas Mental Health University Institute | 2021-01-11 |
| A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression (NCT04599855) | Janssen Research & Development, LLC | 2020-11-04 |
| rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) (NCT04239651) | University of Alberta | 2020-10-15 |
| NESBID: Neuro-Stimulation of the Brain in Depression (NCT04159012) | University of Alberta | 2020-09-01 |
| Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression (NCT04428099) | University of the Balearic Islands | 2020-01-13 |
| A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (NCT03852160) | Janssen-Cilag International NV | 2019-12-01 |
| Improving Brain Stimulation Through Imaging (NCT03851380) | VA Office of Research and Development | 2019-09-30 |
| Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine (NCT04216888) | Dan Iosifescu | 2019-06-26 |
| Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. (NCT03887624) | Zhejiang University | 2019-05-21 |
| Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression (NCT03756129) | Novartis Pharmaceuticals | 2019-02-08 |
| Biomarkers of Theta Burst Stimulation in Major Depressive Disorder (NCT03626181) | University of Calgary | 2018-07-06 |
| A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (NCT03434041) | Janssen Research & Development, LLC | 2018-05-25 |
| Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD (NCT03051256) | Relmada Therapeutics, Inc. | 2018-05-11 |
| Treatment-Resistant Depression Cohort in Europe (NCT03373253) | Janssen-Cilag Ltd. | 2018-02-13 |
| Treatment Resistant Depression in America Latina (NCT03207282) | Janssen-Cilag, S.A. | 2017-09-27 |
| Adaptive tDCS for Treatment-Resistant MDD (NCT02942368) | Washington University School of Medicine | 2017-04-14 |
| NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits (NCT02994433) | Washington University School of Medicine | 2017-01-27 |
| An Epidemiology Study of Treatment Resistant Depression in the United States (US) (NCT03109002) | Janssen Research & Development, LLC | 2017-01-15 |
| Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies (NCT03283670) | Washington University School of Medicine | 2016-11-22 |
| A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (NCT02782104) | Janssen Research & Development, LLC | 2016-06-09 |
| Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression (NCT03360942) | Dartmouth-Hitchcock Medical Center | 2016-04-18 |
| A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (NCT02493868) | Janssen Research & Development, LLC | 2015-10-01 |
| Epidemiology of Treatment Resistant Depression in Taiwan (NCT02691520) | Janssen Research & Development, LLC | 2015-09-29 |
| Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) (NCT02452892) | Tal Medical, Inc. | 2015-09-01 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (NCT02422186) | Janssen Research & Development, LLC | 2015-08-20 |
| Ketamine Infusions for PTSD and Treatment-Resistant Depression (NCT02577250) | Minneapolis Veterans Affairs Medical Center | 2015-05-01 |
| Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial (NCT02263872) | Pakistan Institute of Living and Learning | 2014-10-01 |
| Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (NCT02153502) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-07-01 |
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression (NCT02610712) | National Institute of Neurology and Neurosurgery, Mexico | 2014-05-01 |
| DBS for Treatment Resistant Depression (NCT01983904) | University of Calgary | 2013-08-01 |
| Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) (NCT01898429) | Paul Holtzheimer | 2013-07-01 |
| Treatment Resistant Depression (Pilot) (NCT01179009) | Washington University School of Medicine | 2012-04-01 |
| Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) (NCT03829579) | Janssen Research & Development, LLC | |